Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma.
BRAF mutation
Melanoma
NRAS mutation
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
06 Jan 2024
06 Jan 2024
Historique:
received:
13
09
2023
accepted:
28
12
2023
revised:
04
12
2023
medline:
7
1
2024
pubmed:
7
1
2024
entrez:
6
1
2024
Statut:
aheadofprint
Résumé
Reported rates of BRAF mutation in Irish cutaneous melanoma cohorts are lower than the reported international data. We aimed to assess the mutational status of a cohort of primary cutaneous melanomas and to correlate it with clinical follow-up data.A total of 92 cases of primary cutaneous melanoma diagnosed at a single institution in 2012 were analyzed. Regions containing common mutations in the BRAF, NRAS, KIT, and KRAS genes were investigated by PCR amplification followed by Sanger sequencing. Demographic details, tumor characteristics, and 10-year outcome data were also obtained.Ten cases with BRAF V600E mutations (11.6%) and five (5.49%) NRAS mutations (4 at Q61R, 1 at Q61K) were detected. No statistically significant differences were noted between groups for age, gender, depth of invasion, nodal status, or recurrence status (p ≥ 0.05).These findings suggest that the Irish population has a markedly lower incidence of BRAF and NRAS mutations in melanoma than those reported in other cohorts.
Identifiants
pubmed: 38183457
doi: 10.1007/s00428-023-03732-1
pii: 10.1007/s00428-023-03732-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
https://www.ncri.ie/publications/cancer-trends-and-projections/cancer-projections-ireland-2015-%E2%80%93-2040 . Accessed January 2024
Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114. https://doi.org/10.1056/NEJMoa1203421
doi: 10.1056/NEJMoa1203421
pubmed: 22663011
Cormican D, Kennedy C, Murphy S, Werner R, Power DG, Heffron CCBB (2019) High concordance of BRAF mutational status in matched primary and metastatic melanoma. J Cutan Pathol 46(2):117–122. https://doi.org/10.1111/cup.13393
doi: 10.1111/cup.13393
pubmed: 30430609
O’Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron CCBB (2017) BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol 70(11):935–940. https://doi.org/10.1136/jclinpath-2017-204367
doi: 10.1136/jclinpath-2017-204367
pubmed: 28424234
van den Hurk K, Balint B, Toomey S et al (2015) High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res 25(3):189–199. https://doi.org/10.1097/CMR.0000000000000149
doi: 10.1097/CMR.0000000000000149
pubmed: 25746038
Nagore E, Requena C, Traves V et al (2014) Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol 70(5):858–62.e622. https://doi.org/10.1016/j.jaad.2013.10.064
doi: 10.1016/j.jaad.2013.10.064
pubmed: 24388723
Lopez-Martin JA, Arance Fernández A, Ríos-Martín JJ et al (2020) Frequency and clinicopathological profile associated with Braf mutations in patients with advanced melanoma in Spain. Transl Oncol 13(6):100750. https://doi.org/10.1016/j.tranon.2020.100750
doi: 10.1016/j.tranon.2020.100750
pubmed: 32422543
pmcid: 7229288
Thomas NE, Edmiston SN, Alexander A et al (2015) Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma [published correction appears in JAMA Oncol. 2015 Jun;1(3):285]. JAMA Oncol 1(3):359–368. https://doi.org/10.1001/jamaoncol.2015.0493
doi: 10.1001/jamaoncol.2015.0493
pubmed: 26146664
pmcid: 4486299
Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126(1):154–160. https://doi.org/10.1038/sj.jid.5700026
doi: 10.1038/sj.jid.5700026
pubmed: 16417231
Jakob JA, Bassett RL Jr, Ng CS et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 118(16):4014–4023. https://doi.org/10.1002/cncr.26724
doi: 10.1002/cncr.26724
pubmed: 22180178
Wolfe AR, Chablani P, Siedow MR et al (2021) BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol 16(1):181. Published 2021 Sep 18. https://doi.org/10.1186/s13014-021-01903-5
doi: 10.1186/s13014-021-01903-5
pubmed: 34537078
pmcid: 8449455
Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246. https://doi.org/10.1200/JCO.2010.32.4327
doi: 10.1200/JCO.2010.32.4327
pubmed: 21343559
Carlino MS, Haydu LE, Kakavand H et al (2014) Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 111(2):292–299. https://doi.org/10.1038/bjc.2014.287
doi: 10.1038/bjc.2014.287
pubmed: 24918823
pmcid: 4102942
Menzies AM, Haydu LE, Visintin L et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18(12):3242–3249. https://doi.org/10.1158/1078-0432.CCR-12-0052
doi: 10.1158/1078-0432.CCR-12-0052
pubmed: 22535154
Thomas NE, Edmiston SN, Orlow I et al (2018) Inherited genetic variants associated with melanoma BRAF/NRAS subtypes. J Invest Dermatol 138(11):2398–2404. https://doi.org/10.1016/j.jid.2018.04.025
doi: 10.1016/j.jid.2018.04.025
pubmed: 29753029
pmcid: 6200630
Ekedahl H, Cirenajwis H, Harbst K et al (2013) The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 169(5):1049–1055. https://doi.org/10.1111/bjd.12504
doi: 10.1111/bjd.12504
pubmed: 23855428
Edlundh-Rose E, Egyházi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16(6):471–478. https://doi.org/10.1097/01.cmr.0000232300.22032.86
doi: 10.1097/01.cmr.0000232300.22032.86
pubmed: 17119447
Aksenenko MB, Kirichenko AK, Ruksha TG (2015) Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma. Pathol Res Pract 211(7):521–527. https://doi.org/10.1016/j.prp.2015.03.005
doi: 10.1016/j.prp.2015.03.005
pubmed: 25888143
Schlaak M, Bajah A, Podewski T et al (2013) Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. Br J Dermatol 168(4):708–716. https://doi.org/10.1111/bjd.12140
doi: 10.1111/bjd.12140
pubmed: 23528057
Meckbach D, Bauer J, Pflugfelder A et al (2014) Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. PLoS One 9(1):e86194. Published 2014 Jan 24. https://doi.org/10.1371/journal.pone.0086194
doi: 10.1371/journal.pone.0086194
pubmed: 24475086
pmcid: 3901680
Colombino M, Capone M, Lissia A et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522–2529. https://doi.org/10.1200/JCO.2011.41.2452
doi: 10.1200/JCO.2011.41.2452
pubmed: 22614978
Inumaru JS, Gordo KI, Fraga Junior AC et al (2014) Analysis of the BRAF V600E mutation in primary cutaneous melanoma. Genet Mol Res 13(2):2840–2848. Published 2014 Jan 22. https://doi.org/10.4238/2014.January.22.8
doi: 10.4238/2014.January.22.8
pubmed: 24535907
Lang J, MacKie RM (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125(3):575–579. https://doi.org/10.1111/j.0022-202X.2005.23833.x
doi: 10.1111/j.0022-202X.2005.23833.x
pubmed: 16117801
Yaman B, Akalin T, Kandiloğlu G (2015) Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Am J Dermatopathol 37(5):389–397. https://doi.org/10.1097/DAD.0000000000000241
doi: 10.1097/DAD.0000000000000241
pubmed: 25357015
Web site: https://www.graphpad.com/ . Accessed January 2024
Pracht M, Mogha A, Lespagnol A et al (2015) Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J Eur Acad Dermatol Venereol 29(8):1530–1538. https://doi.org/10.1111/jdv.12910
doi: 10.1111/jdv.12910
pubmed: 25623140
Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature. 545(7653):175–180. https://doi.org/10.1038/nature22071
doi: 10.1038/nature22071
pubmed: 28467829
Liu W, Kelly JW, Trivett M et al (2007) Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127(4):900–905. https://doi.org/10.1038/sj.jid.5700632
doi: 10.1038/sj.jid.5700632
pubmed: 17159915
Catalogue of somatic mutations in cancer (COSMIC). http://www.sanger.ac.uk/cosmic .
Fedorenko IV, Gibney GT, Smalley KS (2013) NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 32(25):3009–3018. https://doi.org/10.1038/onc.2012.453
doi: 10.1038/onc.2012.453
pubmed: 23069660
https://doi.org/10.6004/jnccn.2019.0018 (accessed November 2023)
Smith R, Healy E, Siddiqui S et al (1998) Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 111(1):119–122. https://doi.org/10.1046/j.1523-1747.1998.00252.x
doi: 10.1046/j.1523-1747.1998.00252.x
pubmed: 9665397
Mitra D, Luo X, Morgan A et al (2012) An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 491(7424):449–453. https://doi.org/10.1038/nature11624
doi: 10.1038/nature11624
pubmed: 23123854
pmcid: 3521494